Evolent HealthEVH +4.79%60 EBITDA Margin % is 2.56% as of Mar. 2026. GuruFocus rates EVH with a GF Score™ of 60/100 and a GF Value™ of $11.05 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Evolent Health ranks worse than 83.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evolent Health's EBITDA for the
three
months ended in Mar. 2026 was $13 Mil. Evolent Health's Revenue for the
three
months ended in Mar. 2026 was $496 Mil. Therefore, Evolent Health's EBITDA margin for the quarter that ended in Mar. 2026 was 2.56%.
Evolent Health (NYSE:EVH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Evolent Health EBITDA Margin % Related Terms
Evolent Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Evolent Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVH vs NRC, CTEV, WEAV: EBITDA Margin % Comparison
For the Health Information Services subindustry, Evolent Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolent Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Evolent Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health (EVH) has a EBITDA Margin % of 2.56% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evolent Health and its competitors. According to the industry distribution chart, Evolent Health ranks #561 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 84%.
Is Evolent Health's EBITDA Margin % too high?
Evolent Health's current EBITDA Margin % is 2.56%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Evolent Health's value of 2.56% is 74.9% below this industry median. Based on the distribution chart, Evolent Health ranks #561 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Evolent Health has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's EBITDA Margin % compare to NRC and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #561 out of 668 companies for EBITDA Margin %. This places Evolent Health in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Evolent Health's value of 2.56% is 74.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evolent Health's current EBITDA Margin % of 2.56% is 74.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evolent Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current EBITDA Margin % is 2.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.05, compared to a current price of $5.03 — trading 54.5% below its estimated fair value. The current EBITDA Margin % is 2.56% and 74.9% below the Healthcare Providers & Services industry median of 10.21. Evolent Health's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Evolent Health (EVH), the current EBITDA Margin % is 2.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolent Health (EVH) Overvalued in 2026?
Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued.
The current stock price of $5.03 is trading 54.5% below its estimated GF Value™ of $11.05.
GuruFocus considers Evolent Health to be Possible Value Trap.
Key valuation signals for EVH:
EBITDA Margin %: 2.56%
GF Value™: $11.05 vs. price of $5.03 (54.5% below fair value)
Industry Position: 74.9% below the Healthcare Providers & Services median (#561 of 668)
No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
60GF Score
Get the complete analysis for EVH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVH has been successfully added to your 
